Inactive Instrument
Claritas Pharmaceuticals, Inc. Share Price Toronto S.E.
Stocks
CLAS.H
CA1806342061
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 53.68L 38.12L 33.48L 31.14L 28.57L 37Cr 54.51L 3.7Cr 1.44Cr 18Cr 1.43Cr 1.4Cr 62Cr | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 62.88L 44.65L 39.22L 36.47L 33.47L 43Cr 63.85L 4.33Cr 1.69Cr 21Cr 1.68Cr 1.64Cr 73Cr | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -28.57% | - | - | 37 | |
| +1.07% | -3.49% | -3.35% | +10.44% | 4.69TCr | |
| +0.25% | +1.65% | +399.22% | +634.87% | 4.02TCr | |
| -0.27% | +4.45% | +11.81% | +65.64% | 3.62TCr | |
| +0.35% | +0.87% | +4.46% | -10.16% | 3.47TCr | |
| +3.14% | +1.02% | +4.76% | +40.92% | 2.79TCr | |
| -0.73% | +11.84% | +34.39% | +134.36% | 1.68TCr | |
| +0.47% | -2.74% | - | - | 1.67TCr | |
| +0.42% | -5.52% | -3.43% | +9.03% | 1.31TCr | |
| -2.68% | -2.49% | -11.36% | -33.61% | 1.27TCr | |
| Average | +0.20% | +0.83% | +54.56% | +106.44% | 2.73TCr | |
| Weighted average by Cap. | +0.48% | +0.91% | +74.42% | +136.27% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -2.12Cr -1.51Cr -1.32Cr -1.23Cr -1.13Cr -145.05Cr -2.15Cr -15Cr -5.71Cr -71Cr -5.65Cr -5.53Cr -246.56Cr | 42.1L 29.89L 26.26L 24.42L 22.41L 29Cr 42.75L 2.9Cr 1.13Cr 14Cr 1.12Cr 1.1Cr 49Cr |
| Net Debt | 7L 5L 4L 4L 4L 4.81Cr 7L 48.49L 18.94L 2.37Cr 18.77L 18.36L 8.18Cr | 9L 7L 6L 5L 5L 6.29Cr 9L 63.36L 24.76L 3.09Cr 24.52L 24L 11Cr |
Employees
-
